IL291727B2 - שיטה ותכשירים לטיפול בזיהום וירוס הקורונה - Google Patents

שיטה ותכשירים לטיפול בזיהום וירוס הקורונה

Info

Publication number
IL291727B2
IL291727B2 IL291727A IL29172722A IL291727B2 IL 291727 B2 IL291727 B2 IL 291727B2 IL 291727 A IL291727 A IL 291727A IL 29172722 A IL29172722 A IL 29172722A IL 291727 B2 IL291727 B2 IL 291727B2
Authority
IL
Israel
Prior art keywords
microg
day
oleandrin
acid
antiviral composition
Prior art date
Application number
IL291727A
Other languages
English (en)
Other versions
IL291727B1 (he
IL291727A (he
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/895,920 external-priority patent/US10729735B1/en
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of IL291727A publication Critical patent/IL291727A/he
Publication of IL291727B1 publication Critical patent/IL291727B1/he
Publication of IL291727B2 publication Critical patent/IL291727B2/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL291727A 2020-03-31 2022-03-27 שיטה ותכשירים לטיפול בזיהום וירוס הקורונה IL291727B2 (he)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063002735P 2020-03-31 2020-03-31
US202063010246P 2020-04-15 2020-04-15
US202063014294P 2020-04-23 2020-04-23
US202063017263P 2020-04-29 2020-04-29
US202063021512P 2020-05-07 2020-05-07
US202063029530P 2020-05-24 2020-05-24
US202063034800P 2020-06-04 2020-06-04
US16/895,920 US10729735B1 (en) 2016-09-14 2020-06-08 Method and compostitions for treating coronavirus infection
US202063042656P 2020-06-23 2020-06-23
US202063051576P 2020-07-14 2020-07-14

Publications (3)

Publication Number Publication Date
IL291727A IL291727A (he) 2022-05-01
IL291727B1 IL291727B1 (he) 2023-03-01
IL291727B2 true IL291727B2 (he) 2023-07-01

Family

ID=77930101

Family Applications (2)

Application Number Title Priority Date Filing Date
IL277315A IL277315B (he) 2020-03-31 2020-09-13 שיטה ותכשירים לטיפול בזיהום וירוס הקורונה
IL291727A IL291727B2 (he) 2020-03-31 2022-03-27 שיטה ותכשירים לטיפול בזיהום וירוס הקורונה

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL277315A IL277315B (he) 2020-03-31 2020-09-13 שיטה ותכשירים לטיפול בזיהום וירוס הקורונה

Country Status (8)

Country Link
JP (2) JP7153083B2 (he)
KR (2) KR20220151038A (he)
IL (2) IL277315B (he)
MX (2) MX394337B (he)
RU (1) RU2020130238A (he)
SG (1) SG11202105728YA (he)
TW (2) TWI753747B (he)
WO (1) WO2021201903A1 (he)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014731A (es) * 2020-05-24 2023-02-27 Phoenix Biotechnology Inc Extracto que contiene oleandrina y metodo de produccion de este.
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CA3228041A1 (en) * 2021-08-16 2023-02-23 Phoenix Biotechnology, Inc. Method and compositions for treating animal viral infections
WO2023212353A1 (en) * 2022-04-29 2023-11-02 Emory University Viral entry inhibitors derived from botanicals
CN115364136A (zh) * 2022-09-05 2022-11-22 深圳市药品检验研究院（深圳市医疗器械检测中心） 景天科植物提取物在制备抗新型冠状病毒和流感病毒感染药物中的应用
CN116350637A (zh) * 2023-03-09 2023-06-30 中国人民解放军空军军医大学 胆固醇及其代谢相关物质在制备抑制汉坦病毒感染药物中的用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1394196A (en) 1971-10-03 1975-05-14 Hisamitsu Pharmaceutical Co Process for isolating oleandrin from nerium odorum
DK239687A (da) 1986-05-13 1987-11-14 Huseyin Ziya Ozel Planteekstrakter
JPS6333341A (ja) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (en) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
CA2330916C (en) 1998-05-19 2011-04-05 Research Development Foundation Triterpene compositions and methods for use thereof
US6565897B2 (en) 1998-09-24 2003-05-20 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
AU8494601A (en) 2000-08-18 2002-03-04 Univ Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
DE60204078T2 (de) 2001-04-09 2006-01-26 Loders Croklaan B.V. Konzentrat von Triterpenen
EP2567625A1 (en) 2001-05-11 2013-03-13 University Of Ottawa Preparation containing betulinic acid, obtained from a plant of the family Marcgraviaceae
EP1397149A1 (en) 2001-06-18 2004-03-17 S.A.V Virex Co Ltd Nerium oleander extract, compositions containing the nerium oleander l. extract and a method of preparation of this extract
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
EP1585504A4 (en) 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
WO2004087121A2 (en) 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
BRPI0508854A (pt) 2004-03-17 2007-08-28 Panacos Pharmaceuticals Inc sais farmacêuticos de ácido-3-o-(3',3'-dimetilsuccinil) betulìnico
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
ES2618423T3 (es) 2004-08-13 2017-06-21 Biolase, Inc Estructura de instrumento de mano de láser, y métodos
WO2006085334A2 (en) 2005-02-09 2006-08-17 Dabur Pharma Limited Novel betulinic acid derivatives a-ring-condensed to a heterocyclic group
AU2006230429A1 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing TEMPO
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
US20090131714A1 (en) 2005-06-08 2009-05-21 Krasutsky Pavel A Synthesis of betulonic and betulinic aldehydes
JP5080249B2 (ja) 2005-06-10 2012-11-21 ポーラ化成工業株式会社 新規トリテルペン酸誘導体及びそれを含有してなる皮膚外用剤
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CN101374527A (zh) 2005-12-16 2009-02-25 帕纳克斯医药公司 3-o-(3’,3’-二甲基琥珀酰基)桦木酸的药物盐的制备方法
EP1803461A1 (en) 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutic use of an extract from the leaves of Nerium oleander
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
WO2008063318A2 (en) 2006-10-12 2008-05-29 The Texas A & M University System And Safe Et Al Betulinic acid, derivatives and analogs thereof and uses therefor
CA2668452A1 (en) 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
CA2705272C (en) 2007-11-13 2020-05-12 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US20110224159A1 (en) 2008-09-10 2011-09-15 Universite du Quebec a Chicoutime Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
CA2739029C (en) 2008-10-14 2018-07-10 Nerium Biotechnology, Inc. Process for extracting cardiac glycosides from plants and compositions comprising cardiac glycosides from nerium oleander
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
US8685469B2 (en) 2009-11-30 2014-04-01 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
KR101811462B1 (ko) 2010-01-11 2018-01-25 피닉스 바이오테크놀러지 인코포레이티드. 협죽도 추출물을 포함하는 신경질환 치료용 조성물
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
US20140221328A1 (en) 2011-01-10 2014-08-07 Bandi Parthasaradhi Reddy Pharmaceutically acceptable salts of novel betulinic acid derivatives
HUE026371T2 (en) 2011-01-31 2016-05-30 Bristol Myers Squibb Co C-28 amines from modified C-3 betulinic acid derivatives as anti-HIV matrices
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
CN103946231B (zh) 2011-12-01 2016-10-26 杭州本生药业有限公司 齐墩果酸酰胺化衍生物、及其制备方法和应用
JP6211527B2 (ja) 2011-12-01 2017-10-11 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ２−置換オレアノール酸誘導体、その調製方法及びその用途
WO2013160810A2 (en) 2012-04-24 2013-10-31 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2014027777A2 (ko) 2012-08-14 2014-02-20 한국콜마 주식회사 신규한 우르솔릭산 유도체 및 이의 제조 방법
SMT201700501T1 (it) 2012-09-10 2017-11-15 Reata Pharmaceuticals Inc Derivati c17-eteroarilici dell'acido oleanolico e metodi d'uso degli stessi
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
KR20150121712A (ko) 2013-02-25 2015-10-29 브리스톨-마이어스 스큅 컴퍼니 Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US20190216835A1 (en) * 2016-06-09 2019-07-18 University Of Massachusetts Inhibition of Zika Virus Infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
WO2018053123A1 (en) 2016-09-14 2018-03-22 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10702567B2 (en) * 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
CA3075729A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection

Also Published As

Publication number Publication date
IL291727B1 (he) 2023-03-01
MX2022009176A (es) 2022-08-17
IL277315A (he) 2021-09-30
JP2022522074A (ja) 2022-04-14
IL277315B (he) 2022-05-01
TW202137991A (zh) 2021-10-16
IL291727A (he) 2022-05-01
JP2022186737A (ja) 2022-12-15
SG11202105728YA (en) 2021-11-29
RU2020130238A3 (he) 2022-03-14
TW202211926A (zh) 2022-04-01
TWI753747B (zh) 2022-01-21
MX394337B (es) 2025-03-24
KR20220151038A (ko) 2022-11-11
KR20210124010A (ko) 2021-10-14
JP7153083B2 (ja) 2022-10-13
MX2020009095A (es) 2022-07-28
TWI790048B (zh) 2023-01-11
KR102464428B1 (ko) 2022-11-04
WO2021201903A1 (en) 2021-10-07
RU2020130238A (ru) 2022-03-14

Similar Documents

Publication Publication Date Title
US10729735B1 (en) Method and compostitions for treating coronavirus infection
US11324789B2 (en) Method and compositions for treating equine encephalitis
TWI790048B (zh) 用於預防冠狀病毒感染之方法及組成物
ES2965161T3 (es) Método y composiciones para el tratamiento de infección por coronavirus
US20220054521A1 (en) Method and Compositions for Treating Coronavirus Infection
US11806359B2 (en) Method and compositions for treating Coronavirus infection
EP4009981B1 (en) Method and compositions for treating coronavirus infection
US20220047616A1 (en) Method and Compositions for Treating HTLV-1 Virus Infection
AU2021201209B2 (en) Method and compositions for treating coronavirus infection
HK40062840A (en) Method and compositions for treating coronavirus infection
HK40051984B (en) Method and compositions for treating coronavirus infection
HK40051984A (en) Method and compositions for treating coronavirus infection